BioMedNewsBreaks Archive - Page 77 of 258

ThursdayJun 20, 2024 11:11 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, today provided an update on its AVERSA(TM) Fentanyl product development program. This comes as the company plans to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to a New Drug Application (“NDA”) filing. According to the update, Nutriband is currently working with its partner Kindeva Drug Delivery to develop the commercial scale manufacturing process for the final product, which will incorporate Nutriband’s AVERSA(TM) abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. The update noted…

ThursdayJun 20, 2024 9:42 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, presented new long-term CNM-Au8 treatment results for survival and neurofilament light (“NfL”) levels from the HEALEY ALS Platform Trial open label extension (“OLE”) at the European Network for the Cure of ALS (“ENCALS”) meeting in Stockholm, Sweden. Entitled “Long-Term CNM-Au8 Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” the presentation data highlights up to 42 months (3.5 years) of survival…

TuesdayJun 18, 2024 12:44 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. According to the announcement, Annovis Bio senior VP of research & development Dr. Cheng Fang will present an extended 45-minute session at the conference; the presentation is scheduled to begin at 8 a.m. on July 31. He will be joined by Kathleen A. Welsh-Bohmer, PhD,…

MondayJun 17, 2024 10:36 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents in lieu thereof, as part of registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement. The shares will be offered at a combined purchase price of $3.75 per share. According to the announcement, the warrants…

FridayJun 14, 2024 1:20 pm

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its subsidiary, AgLAB, have entered into a master lease agreement with SC Labs; the companies are working together to jointly market the AgLAB 1000-D2(TM) mass spectrometer and the AgLAB Maximum Value Process testing method to SC Labs customers. AgLAB has pioneered applications featuring the Astrotech Mass Spectrometer Technology that specifically target the hemp and cannabis markets while SC Labs, one of the largest multistate cannabis and hemp-testing labs in the United States, delivers industry-leading, science-based innovations in cannabis and hemp testing. The partnership between the two entities extends SC Labs’ analytical services directly…

ThursdayJun 13, 2024 2:05 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received a nonbinding letter of intent (“LOI”) from the European Investment Bank (“EIB”). According to the announcement, the LOI contains terms for converting EIB's loan of approximately $27.6 million into equity in the form of prefunded warrants; the warrants, which will be exercisable into American Depositary Shares (“ADSs”), represent 19.5% of the fully diluted capital of the company as well as capped variable return mostly in the form of…

ThursdayJun 13, 2024 1:29 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (‘FDA’) in the fourth quarter of 2024. This step paves the way for potential commercial availability in the U.S. of suramin, the sole form for treating stage 1 Human African Trypanosomiasis (‘HAT’) caused by Trypanosoma brucei rhodesiense. This disease, fatal and neglected, represents a critical healthcare challenge,” a recent article reads. “This completion of…

WednesdayJun 12, 2024 1:52 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Unveils New Online Medical Record Request Form, Is Featured in Latest Episode of Bell2Bell Podcast

HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has unveiled a new online medical record request form, which is integrated with DocuSign. According to the announcement, patients can now seamlessly request their medical records with only a few clicks, and the records are automatically added to the patients' HealthLynked Network profile. The integration with DocuSign, a pioneer in electronic-signature technology, makes the request process quick and easy. The new online request form allows patients to request records from multiple healthcare providers and laboratories while providing enhanced security; all records are easily accessed and managed within the user's HealthLynked…

TuesdayJun 11, 2024 2:32 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) is scheduled to present at the 72nd Emerging Growth Conference, hosted by leading independent small cap media portal EmergingGrowth.com. Taking place on June 12 - 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Clene’s President and CEO Rob Etherington and CFO Morgan Brown will provide a keynote speech at the conference starting at 2:20 p.m. ET on June 12. To view the full press release, visit https://ibn.fm/a13Kr About Clene Inc. Clene (along with its…

TuesdayJun 11, 2024 1:37 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study was designed to evaluate Buntanetap, the company’s lead drug candidate. According to the report, key findings indicate that Buntanetap showed statistically significant efficacy and safety in the treatment of both carriers and noncarriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. The company has scheduled an investor call for today at 4:30 p.m. ET to provide more detailed information and outline future development plans…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

BioMedNewsBreaks — CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Unveils New Online Medical Record Request Form, Is Featured in Latest Episode of Bell2Bell Podcast

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search